New experimental flu vaccine aims to outsmart the flu virus
NCT ID NCT05968989
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This early-stage study tested an experimental flu vaccine called FluMos-v2 in 30 healthy adults aged 18 to 50. The vaccine is designed to protect against multiple flu strains at once, unlike current vaccines that target only one. Participants received two shots four months apart and were monitored for safety and immune response over 10 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts